A Comparison of the Efficacy of Once-Daily Fluticasone Furoate/Vilanterole with Twice-Daily Fluticasone Propionate/Salmeterol in Elderly Asthmatics.

Published on Jan 1, 2018in Drug Research
· DOI :10.1055/S-0043-118536
Yoshihisa Ishiura17
Estimated H-index: 17
(Kansai Medical University),
Masaki Fujimura53
Estimated H-index: 53
+ 4 AuthorsKazuo Kasahara28
Estimated H-index: 28
(Kanazawa University)
Background Asthma in the elderly population has been focused because it affects quality of life and results in a higher hospitalization rate and mortality. Fluticasone furoate (FF)/vilanterole (VI) is a novel inhaled corticosteroids (ICS)/long-acting β2 agonist (LABA) combination being developed for once-daily administration for asthma with greater anti-inflammatory activity and longer duration of bronchidilation. The ElliptaTM dry powder inhaler (DPI) has also been available as a new device with high levels of satisfaction and preference. Methods A 12-week, randomized, open-label cross-over, pilot study was conducted in 18 elderly patients with bronchial asthma to compare the effectiveness of once-daily FF/VI 200/25 µg via the ElliptaTM DPI vs. twice-daily fluticasone propionate (FP)/salmeterol (SAL) 500/50 µg via the DiskusTM DPI. The study period included a 4-week run-in, the first 4-week treatment, and the second 4-week treatment. Respiratory functions, fractional exhaled nitric oxide (FeNO) and asthma control test (ACT) scores were measured 0, 4, and 8 weeks after randomization. Preferences for their device were also assessed using a self-completed questionnaire. Results Spirometric paramters, FeNO levels and ACT scores were not significantly different during the run-in period, the FP/SAL treatment period, and the FF/VI treatment period. FF/VI treatment via the ElliptaTM DPI was preferred to the FP/SAL treatment via the DiskusTM DPI (p Conclusions These data indicate that FF/VI treatment via the ElliptaTM DPI is preferred in elderly patients with asthma based on its ease-of-use, suggesting the potential to improve patient adherence and, as a result, overall disease management.
📖 Papers frequently viewed together
23 Citations
65 Citations
2 Citations
#1Fritz HorakH-Index: 21
#2Daniel Doberer (Medical University of Vienna)H-Index: 17
Last. Michael Studnicka (University of Salzburg)H-Index: 31
view all 10 authors...
This statement was written by a group of pulmonologists and pediatric pulmonologists belonging to the corresponding professional associations OGP (Austrian Society for Pulmonology) and OGKJ (Austrian Society for pediatric and adolescent medicine) to provide a concise overview of the latest updates in the 2015 GINA Guidelines and to include aspects that are specific to Austria.
59 CitationsSource
#1Yoshihisa IshiuraH-Index: 17
#2Masaki FujimuraH-Index: 53
Last. Kazuo Kasahara (Kanazawa University)H-Index: 28
view all 6 authors...
Abstract Background Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is important because patients with ACOS have significantly worse outcomes compared with those with asthma or chronic obstructive pulmonary disease (COPD) alone. Inhaled corticosteroids (ICS), together with a long-acting β2 agonist (LABA), are recommended, but no therapeutic studies for ACOS have been conducted. Recently, fluticasone furoate/vilanterole (FF/VI) has been approved as the first once-daily ICS/LA...
23 CitationsSource
#1Christina Brandenberger (MHH: Hannover Medical School)H-Index: 18
#2Ning Li (MSU: Michigan State University)H-Index: 35
Last. Jack R. Harkema (MSU: Michigan State University)H-Index: 62
view all 6 authors...
SummaryBackground The prevalence of asthma in the elderly is increasing and associated with higher mortality than in children or young adults. However, the effects of age on the development and character of allergic asthma have been understudied. It has been suggested that mixed Th2/Th17 responses cause more severe forms of asthma, but the role of Th17 response in allergic airway disease and aging is not well understood. Objective To investigate age-dependent characteristics and Th17 immune resp...
31 CitationsSource
#1Helena PitéH-Index: 9
Last. João FonsecaH-Index: 52
view all 6 authors...
Summary Background: Asthma and rhinitis are frequent respiratory diseases in children and adults. Despite the increase in the aging population, there are few epidemiologic data on both diseases in the elderly. So far, no population-based study has analyzed the association between asthma and rhinitis symptoms and severity in this age group. This study aimed to estimate the prevalence of physician-diagnosed asthma in the population aged � 65 years in mainland Portugal and to evaluate its associati...
25 CitationsSource
#1Mark T. Dransfield (UAB: University of Alabama at Birmingham)H-Index: 61
#2Gregory FeldmanH-Index: 14
Last. Fernando J. Martinez (UM: University of Michigan)H-Index: 148
view all 9 authors...
Summary Background Fluticasone furoate/vilanterol (FF/VI) is an inhaled corticosteroid/long-acting beta 2 -agonist (ICS/LABA), recently approved as once-daily maintenance therapy for COPD. We compared the lung function effects of FF/VI with those of twice-daily fluticasone propionate/salmeterol (FP/SAL). Methods Three 12 week studies comparing FF/VI and FP/SAL were conducted. Patients aged ≥40 years with moderate-to-very severe COPD were randomized to receive double-blind, double-dummy FF/VI 100...
27 CitationsSource
#1Anahí YáñezH-Index: 11
#2Sang-Hoen Cho (Hanyang University)H-Index: 1
Last. Stephen T. Holgate (University of Southampton)H-Index: 164
view all 20 authors...
In the past, asthma was considered mainly as a childhood disease. However, asthma is an important cause of morbidity and mortality in the elderly nowadays. In addition, the burden of asthma is more significant in the elderly than in their younger counterparts, particularly with regard to mortality, hospitalization, medical costs or health-related quality of life. Nevertheless, asthma in the elderly is still been underdiagnosed and undertreated. Therefore, it is an imperative task to recognize ou...
93 CitationsSource
#1Henrik Svedsater (GSK: GlaxoSmithKline)H-Index: 18
#2Peter DaleH-Index: 7
Last. Mark W WoepseH-Index: 1
view all 5 authors...
Medications for respiratory disorders including asthma and chronic obstructive pulmonary disease (COPD) are typically delivered to the lung by means of a handheld inhaler. Patient preference for and ability to use the inhaler may influence their adherence to maintenance therapy, and adherence may affect treatment outcomes. In this study, patient experience of using a dry powder inhaler (DPI), the ELLIPTA™ DPI, in clinical trials of a new maintenance therapy for asthma and COPD was investigated. ...
65 CitationsSource
#1Ashley Woodcock (University of Manchester)H-Index: 93
#2Eugene R. Bleecker (Wake Forest University)H-Index: 119
Last. William W. Busse (UW: University of Wisconsin-Madison)H-Index: 131
view all 9 authors...
BACKGROUND: The combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting ?2 agonist, is under development as a once-daily treatment of asthma and COPD. The aim of this study was to compare the efficacy of FF/VI with fluticasone propionate (FP)/salmeterol (SAL) in patients with persistent asthma uncontrolled on a medium dose of ICS. METHODS: In a randomized, double-blind, double-dummy, parallel group study, 806 patients received FF/VI (100/...
65 CitationsSource
Purpose of review The use of anticholinergic medications is well established as maintenance therapy for chronic obstructive pulmonary disease (COPD). There is a growing interest in the use of anticholinergic medications in the treatment of moderate to severe asthma. The purpose of this review is to summarize the scientific evidence for the use of anticholinergic therapy in the management of asthma. Recent findings Early case reports and small studies evaluated the use of the anticholinergic agen...
12 CitationsSource
#1Robert J. Slack (GSK: GlaxoSmithKline)H-Index: 13
#2Victoria J. Barrett (GSK: GlaxoSmithKline)H-Index: 10
Last. Richard G. Knowles (GSK: GlaxoSmithKline)H-Index: 42
view all 7 authors...
Vilanterol trifenatate (vilanterol) is a novel, long-acting β 2 -adrenoceptor ( β 2 -AR) agonist with 24 h activity. In this study, we describe the preclinical pharmacological profile of vilanterol using radioligand binding and cAMP studies in recombinant assays as well as human and guinea pig tissue systems to characterize β 2 -AR binding and functional properties. Vilanterol displayed a subnanomolar affinity for the β 2 -AR that was comparable with that of salmeterol but higher than olodaterol...
80 CitationsSource
Cited By7
#1Hiroyuki OhbayashiH-Index: 11
#2Takamitsu AsanoH-Index: 8
Last. Mitsue ArigaH-Index: 1
view all 4 authors...
Inhalation therapy involves two types of adherence: adherence to the drug and adherence to the procedures for the inhalation device. User satisfaction and preference are key factors for maintaining good adherence of both types, and they should be evaluated based on three conditions being well maintained: asthma control level (ACL), adherence, and adequate device operability during usage duration. We compared user satisfaction and preference between a pressurized metered-dose inhaler (pMDI) and a...
#1Yoshihisa Ishiura (Kansai Medical University)H-Index: 1
#1Yoshihisa Ishiura (Kansai Medical University)H-Index: 17
Last. Shosaku Nomura (Kansai Medical University)H-Index: 52
view all 10 authors...
Purpose: Asthma-chronic obstructive pulmonary disease overlap (ACO), characterized by airway limitation, is an important condition with high incidence and mortality. Although some guidelines recommend triple therapy with inhaled corticosteroids/long-acting muscarinic antagonists/long-acting beta2 agonists, this treatment approach is based on the extrapolation of data from studies of asthma or chronic obstructive pulmonary disease (COPD) alone. Methods: A 12-week, randomized, open-label cross-ove...
4 CitationsSource
#1Aaron B. Holley (Walter Reed National Military Medical Center)H-Index: 17
#2Linda Rogers (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 9
Last. Linda Rogers (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 8
view all 2 authors...
Over the past 5–10 years the methods for administering traditional asthma therapies have evolved rapidly. Inhaler design has improved, allowing for increased deposition of medicine in the lungs, and less in the oropharynx. Large, randomized trials and systematic reviews have improved our knowledge on dosing and frequency, making therapy adjustments more precise. Lastly, long-acting muscarinic antagonists (LAMAs), which are traditionally used to treat chronic obstructive pulmonary disease (COPD),...
#1Yoshihisa Ishiura (Kansai Medical University)H-Index: 17
#2Masaki Fujimura (Kanazawa University)H-Index: 53
Last. Shosaku Nomura (Kansai Medical University)H-Index: 52
view all 9 authors...
OBJECTIVE: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is of increasing interest because ACO patients have significantly worse outcomes, leading to greater social and economic burdens compared with asthma or COPD alone. Some guidelines for ACO recommend triple therapy with inhaled corticosteroids, long-acting β2 agonists, and long-acting muscarinic antagonists. However, this approach is based on extrapolating data from patients with asthma or COPD alone. Therapeutic studies...
15 CitationsSource
#1Pinkus Goldberg (IU: Indiana University)
The older adult asthmatic population is increasing, as is the complexity of asthma treatments. This segment of asthmatics has been understudied, and modalities of therapy are affected by the aging process and comorbid diseases. Corticosteroids are the mainstay of emergency care and of chronic persistent asthma care. Inhaled bronchodilators have proven effective both in the acute setting and as an add-on therapy for chronic control. Leukotriene inhibitors have value especially where inhaler techn...
#1Alan P. Baptist (UM: University of Michigan)H-Index: 20
#2Paula J. Busse (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 30
Asthma in older adults (often classified as those 65 years or older) is relatively common, underdiagnosed, and suboptimally treated. It is an important health problem, as the population of the United States continues to age. Unfortunately, asthma morbidity and mortality rates are highest in this age group. Alterations in the innate and adaptive immune responses occur with aging, and contribute to pathophysiologic differences and subsequent treatment challenges. The symptoms of asthma may differ ...
17 CitationsSource
#2Sagar R. PardeshiH-Index: 3
Last. Raju Onkar SonawaneH-Index: 6
view all 3 authors...
The aim of this work was to evaluate the in vitro performance of nebulized nanosuspension formulation when nebulized using ultrasonic nebulizer. The present investigation deals with successful formulation of Beclomethasone dipropionate loaded HPMCP nanospheres prepared by solvent evaporation technique using PEG 400 as a stabilizer. Beclomethasone dipropionate is a water insoluble drug molecule was encapsulated in HPMCP nanospheres to have pH dependent solubility at basic pH for targeted drug del...
5 CitationsSource